Interleukin-17C (IL-17C)

Ultrasensitive Immunoassay

Simoa

Rules-Based Medicine’s internally developed and manufactured ultrasensitive immunoassay to interleukin-17C (IL-17C) based on the Simoa® bead technology can accurately quantitate sub-pg/mL levels of IL-17C in serum or plasma. The assay has minimal cross-reactivity with human IL-17A and IL-17F. The IL-17C Simoa assay may be a valuable tool for pharmacodynamic clinical studies in autoimmune and chronic inflammatory diseases and oncology.

IL-17C is one of six family members (17A-F) that constitute the IL-17 family of cytokines. IL-17C shares 23% homology with IL-17A and, like IL-17A and IL-17F, is a pro-inflammatory cytokine that is important for host defense. Inappropriate expression of IL-17C is implicated in the development of various inflammatory disorders. However, unlike other IL-17 family members, IL-17C is produced predominately by epithelial cells rather than immune cells, thus acting rapidly in an autocrine manner in response to epithelial injury. IL-17C binds to the IL-17RE receptor and appears to have overlapping signaling with IL-17A, inducing several cytokines and chemokines including CXCL1, IL-1, IL-8, CCL20, and IL-36. Additionally, IL-17C stimulates T helper 17 cells to increase the synthesis of IL-17A/F and IL-22 which promotes autoimmunity.

IL-17C mRNA and protein have been shown to be increased in several inflammatory diseases including psoriasis, atopic dermatitis, immune-mediated glomerular disease, Crohn’s disease, and rheumatoid arthritis. IL-17C is also thought to be involved in tumorigenesis, particularly lung cancer and hepatocellular carcinoma.

Swiss-Prot Accession Number: Q9P0M4

Alternate names for this biomarker include:

Cytokine CX2

Simoa™ Services
Biomarker LLOQ*
(Serum and Plasma)
LLOQ*
(Undiluted Samples)
Volume Required
Serum or plasma Other fluids**
Interleukin-17C (IL-17C) 0.26 pg/mL 0.13 pg/mL 150 µL 150 µL

* Lower limit of quantitation (LLOQ) represents the lowest amount of an analyte that can be quantitatively determined with acceptable precision. LLOQ is determined by performing 2-fold serial dilutions of Standard to be tested in triplicate over three runs. The percent coefficient of variation (CV) is calculated for each of the dilution replicates, and the LLOQ is determined as the concentration at which the CV is 30%.

** Cerebrospinal fluid, urine, tissue culture supernatants,  bronchoalveolar lavage, synovial fluid, tissue extracts, tears, skin washings, etc.

All assay services are performed in our CLIA-certified laboratory.
Intended for Research Use Only.